SINGLE-CELL RESPONSE ANALYSIS
Clinical Trials
How is QuRIE-seq applied (approach and technology)?
QuRIE-seq
It stratifies patients by analyzing their transcriptomic profiles to identify prognostic biomarkers for personalized treatment.
Offers high sensitivity and scalability for longitudinal cohort studies,
Our single-cell response technology impact
on the clinical phase:
Patient Stratification
Identifies prognostic biomarkers that help in selecting the right patients for specific therapies.
Therapeutic Monitoring
Tracks therapeutic product performance and persistence by comparing infusion and patient-derived profiles.
Enhanced Trial Sensitivity
Enables highly sensitive analysis of patient samples, ideal for large-scale and longitudinal clinical studies.